525 Market Street
About Medivation, Inc.Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.
For more information, please visit us at http://www.medivation.com/
Founders: Clarence Patrick and David Hung
CEO and Co-founder: David Hung
CMO (Medical): Mohammad Hirmand
CFO: Jennifer Jarrett
Please click here for medivation job opportunities.
Please click here for clinical trial information.
351 articles with Medivation, Inc.
Five months after the company launched, Acrivon Therapeutics secured $100 million in Series B financing to support the clinical development of a cancer asset it licensed from Eli Lilly.
The latest biopharma insider trading scandal stems from Pfizer’s acquisition of Medivation in 2016.
Tokyo-based Astellas Pharma announced that its roxadustat met its primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease (CKD) patients with anemia not on dialysis. The focus of the drug is on anemia.
Axovant Sciences, one of Vivek Ramaswamy’s biotech startups, is taking another shot, this time at Parkinson’s disease.
Why Former Medivation CEO and a Once-Failed Alzheimer's Drug Could be a Recipe for Disaster for Axovant
Just Days after a $14 Billion Medivation Buy, Pfizer Buys AstraZeneca PLC's Antibiotics Business for $1.5 Billion-Plus